Nonsecretory plasma cell myeloma - Becoming even more rare with serum free light-chain assay - A brief review

被引:0
|
作者
Shaw, Gene R. [1 ]
机构
[1] Marshfield Labs, Marshfield, WI 54449 USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context-Nonsecretory plasma cell myeloma is characterized by an absence of detectable monoclonal protein in both the serum and urine. It is generally reported to comprise approximately 1% to 5% of all cases of plasma cell myeloma and, because of its rarity, requires a high index of suspicion and bone marrow biopsy to establish the diagnosis. Objective.-Review the diagnostic strategy when nonsecretory plasma cell myeloma is a clinical consideration in light of a relatively new serum free light chain assay. Data Sources.-Case study and review of the literature. Conclusions.-Initial data using a recently developed nephelometric serum free light chain assay suggests that only about one fourth of nonsecretory plasma cell myeloma cases may be truly nonsecretory. The definition of nonsecretory plasma cell myeloma should be modified to exclude cases with evidence of clonality using the serum free light chain assay.
引用
收藏
页码:1212 / 1215
页数:4
相关论文
共 50 条
  • [1] Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma
    Drayson, M
    Tang, LX
    Drew, R
    Mead, GP
    Carr-Smith, H
    Bradwell, AR
    [J]. BLOOD, 2001, 97 (09) : 2900 - 2902
  • [2] Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions
    Tosi, Patrizia
    Tomassetti, Simona
    Merli, Anna
    Polli, Valentina
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (01) : 37 - 41
  • [3] Detection and monitoring of nonsecretory myeloma using an assay for free light chains in serum.
    Bradwell, AR
    Carr-Smith, HD
    Smith, L
    Mead, GP
    [J]. CLINICAL CHEMISTRY, 2001, 47 (06) : A43 - A44
  • [4] Serum free light chain immunoassays for monitoring patients with light chain producing and nonsecretory multiple myeloma.
    Bradwell, AR
    Drayson, MT
    Mead, GP
    Galvin, G
    Gasparetto, C
    [J]. BLOOD, 2002, 100 (11) : 382B - 382B
  • [5] Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases
    Tate, Jillian R.
    Mollee, Peter
    Dimeski, Goce
    Carter, Andrew C.
    Gill, Devinder
    [J]. CLINICA CHIMICA ACTA, 2007, 376 (1-2) : 30 - 36
  • [6] Serum-free light-chain assay: clinical utility and limitations
    Bhole, Malini V.
    Sadler, Ross
    Ramasamy, Karthik
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (05) : 528 - 542
  • [7] Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias
    Ozsan, Guner Hayri
    Dispenzieri, Angela
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 65 - 73
  • [8] The Roles of Serum Free Light Chain Assay on The Prognosis of Multiple Myeloma
    Watanaboonyongcharoen, P.
    Suwannabutra, S.
    Theerasaksilp, S.
    Paripokee, N.
    Nakorn, T. Na
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S66 - S66
  • [9] Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
    Murata, Kazunori
    Clark, Raynell J.
    Lockington, Karen S.
    Tostrud, Linda J.
    Greipp, Philip R.
    Katzmann, Jerry A.
    [J]. CLINICAL CHEMISTRY, 2010, 56 (01) : 16 - 18
  • [10] Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations
    Tate, J. R.
    Bazeley, S.
    Sykes, S.
    Mollee, P.
    [J]. CLINICAL CHEMISTRY, 2008, 54 (06) : A123 - A124